vidarabine phosphate and imatinib mesylate

vidarabine phosphate has been researched along with imatinib mesylate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA	1
Kaplow, R	1
Godwin, AK; Hirst, JJ; Ma, Y; Pessetto, ZY; von Mehren, M; Weir, SJ	1

Reviews

1 review(s) available for vidarabine phosphate and imatinib mesylate

Article	Year
Innovations in antineoplastic therapy. The Nursing clinics of North America, 2005, Volume: 40, Issue:1 Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate	2005

Article

Year

Innovations in antineoplastic therapy.

The Nursing clinics of North America, 2005, Volume: 40, Issue:1

Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005

Other Studies

2 other study(ies) available for vidarabine phosphate and imatinib mesylate

Article	Year
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4 Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate	2003
Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Molecular cancer therapeutics, 2014, Volume: 13, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Repositioning; Drug Synergism; Female; Gastrointestinal Stromal Tumors; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Mice; Mice, Nude; Piperazines; Pyrimidines; Vidarabine Phosphate; Xenograft Model Antitumor Assays	2014

Article

Year

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.

Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate

2003

Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.

Molecular cancer therapeutics, 2014, Volume: 13, Issue:10

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Repositioning; Drug Synergism; Female; Gastrointestinal Stromal Tumors; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Mice; Mice, Nude; Piperazines; Pyrimidines; Vidarabine Phosphate; Xenograft Model Antitumor Assays

2014